TELA Bio Expands European Reach with OviTex Inguinal Matrix Launch

Tela Bio (TELA) has launched OviTex Inguinal Matrix in Europe, the only reinforced tissue matrix designed for inguinal hernia repair procedures using laparoscopic and robotic assistance. Analysts forecast an average target price of $5.60, with a high estimate of $7.00 and a low estimate of $2.00, representing a 256.69% upside from the current price of $1.57. The company reported a 12% YoY revenue growth in Q1 2025, reaching $18.5 million, and reaffirmed its 2025 revenue expectation of $85 to $88 million.

TELA Bio (NASDAQ: TELA) has announced the European commercial launch of its OviTex Inguinal Reinforced Tissue Matrix, a product designed specifically for inguinal hernia repair using laparoscopic and robotic-assisted procedures. This strategic move follows the successful U.S. introduction of OviTex Inguinal in 2024, which generated over $1 million in first-year sales [1].

OviTex Inguinal is available in two configurations: three- or four-layer anatomically shaped devices. These configurations are designed to be compatible with trocars, enhancing their use in laparoscopic and robotic procedures. The product builds on the existing OviTex portfolio, utilizing ovine rumen with minimal polymer content to reduce long-term foreign body complications while maintaining necessary strength [1][2].

TELA Bio's product has a robust clinical foundation. Over 69,000 implantations and 40+ published works support its clinical efficacy. A retrospective study of 259 patients undergoing robotic inguinal hernia repair showed a low 1.2% recurrence rate at a 1.5-year follow-up [1][2]. The timing of this announcement coincides with the European Hernia Society Annual Congress in Paris, potentially accelerating early adoption among European hernia surgeons.

Analysts forecast an average target price of $5.60 for TELA, with a high estimate of $7.00 and a low estimate of $2.00. This represents a 256.69% upside from the current price of $1.57. TELA reported a 12% YoY revenue growth in Q1 2025, reaching $18.5 million, and reaffirmed its 2025 revenue expectation of $85 to $88 million [1][2].

References:
[1] https://www.stocktitan.net/news/TELA/tela-bio-announces-european-commercial-launch-of-ovi-tex-inguinal-aziyg4n9fhdm.html
[2] https://www.globenewswire.com/news-release/2025/06/03/3093188/0/en/TELA-Bio-Announces-European-Commercial-Launch-of-OviTex-Inguinal-for-Robotic-and-Laparoscopic-Inguinal-Hernia-Repair.html